Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Viral Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos. The supporters have no influence over the production of the content.

Welcome to the Lymphoma Channel: focus on Viral Lymphoma

VJHemOnc is excited to share updates in the field of viral lymphoma with video interviews and roundtable discussions with leading experts. Discover discussions on risk factors for viral lymphoma, cellular therapies and more on The Viral Lymphoma Channel.

Updated results of the ALLELE trial: tabelecleucel for Epstein–Barr virus-driven PTLD 3:58
Updated results of the ALLELE trial: tabelecleucel for Epstein–Barr virus-driven PTLD
Armin Ghobadi • 8 Dec 2024
Using cfDNA to monitor and diagnose viral-associated lymphomas 1:42
Using cfDNA to monitor and diagnose viral-associated lymphomas
Rena Xian • 9 Dec 2023
Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs 1:28
Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs
Antonio Pérez-Martínez • 23 Apr 2023
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure 6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
Oral nanatinostat and valganciclovir for EBV-associated lymphomas 1:47
Oral nanatinostat and valganciclovir for EBV-associated lymphomas
Pierluigi Porcu • 19 Jul 2019
Dutch HOVON lymphoma study group update 2:36
Dutch HOVON lymphoma study group update
Pieternella Lugtenburg • 20 Jun 2019
Viral lymphomas: risk factors and treatments 8:24
Viral lymphomas: risk factors and treatments
Catherine Bollard et al. • 21 Sep 2018
Cellular therapy and drug access for viral lymphomas 9:57
Cellular therapy and drug access for viral lymphomas
Catherine Bollard et al. • 21 Sep 2018

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals